Financials data is unavailable for this security.
View more
Year on year Edesa Biotech Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 17.55m to a smaller loss of 8.37m.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -94.60% |
---|---|
Return on equity | -129.29% |
Return on investment | -128.81% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Edesa Biotech Inc fell by 1.73m. Cash Flow from Financing totalled 4.83m or -- of revenues. In addition the company used 6.64m for operations while cash from investing was breakeven.
Cash flow per share | -2.15 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.8829 |
---|---|
Tangible book value per share | 0.235 |
More ▼
Balance sheet in USDView more
Current ratio | 1.29 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼